Where Pharmaceutical Programmes Start to Slow Down
Across clinical development, medical affairs and global programme delivery, one issue is showing up more consistently right now. It is rarely a lack of expertise. More often, it is a lack of alignment — and by the time it becomes visible, it is usually already affecting timelines.
Clinical, medical, regulatory and commercial teams can all be doing strong work individually and still create delay collectively. Not because people are underperforming, but because they are moving at different speeds, under different pressures and without enough structural overlap to catch the gaps before they become bottlenecks.
“The bottleneck is not capability. It is the moment when throughput increases but capacity does not adjust in the same way.”
That usually becomes visible at predictable pressure points — conference periods, team transitions, key milestones, holiday cover and launch preparation. By the time the problem is obvious, it is often already affecting timelines.
Why Australia Is Becoming a Stronger Option for Early-Phase Trials
One of the clearest shifts we are seeing is the continued growth of early-phase and exploratory trial activity in Australia. The reasons are practical.
Study start-up can be faster than in the US and much of Europe
The regulatory pathway is well understood, particularly for Phase I and II
The cost profile can be attractive, particularly in earlier development phases
Strong site and investigator capability across the country
From a development strategy perspective, the case is clear. The part that is easier to underestimate is the operating model around it.
Once programmes are spread across regions, time zones and governance frameworks, execution becomes more demanding. The strategic decision may be sound, but the supporting structure does not always evolve at the same pace. That is often where delay begins.
Considering Australia for your next early-phase programme? We work with sponsors navigating this exact challenge across clinical development and regulatory strategy.
Talk to our team about your programme →Where Bottlenecks Usually Appear in Clinical and Medical Affairs Teams
There are three places where we see this most consistently.
1. Medical Affairs and MLR Review
During high-volume periods, review processes come under pressure quickly. Materials arrive not fully ready. Signatory responsibility is concentrated in too few people. Workflows begin to fragment.
The result is predictable — delays increase, timelines become less reliable and pressure builds between teams at exactly the point when speed matters most.
2. Clinical Development and Medical Monitoring
As programmes scale, safety data is generated continuously. Oversight structures do not always scale with it. Signal interpretation slows. Escalation pathways become less clear across regions. Decision-making latency starts to creep in.
This is rarely dramatic at first. It is usually gradual — but it becomes very obvious once the programme is under pressure.
3. Global and Local Execution
As soon as work needs to move across markets, global strategy has to stay aligned with local requirements, local codes and local expectations. If that alignment is weak, teams end up dealing with inconsistent interpretation, slower approvals and avoidable compliance risk.
substantiated code complaints relating to MMD-approved materials in over 12 years. Compliance is not a constraint on speed — it is a condition for it.
What High-Performing Pharmaceutical Teams Do Differently
The strongest teams do not simply add more people when pressure appears. They make structural adjustments earlier.
- Scaling review and signatory capacity before peak periods rather than during them
- Embedding medical input earlier so materials arrive for review genuinely ready
- Ensuring medical monitoring models keep pace with data flow rather than lagging behind it
- Aligning global and local regulatory thinking before regional differences become execution blockers
In other words, they do not wait for friction to become visible before addressing it.
Early Warning Signs of a Misaligned Programme
A Quick Check
If any of these sound familiar, it is usually a sign that alignment is starting to break down — and worth addressing before timelines tighten further:
- Review timelines are becoming less predictable
- Increasing back-and-forth between medical and marketing teams
- Materials requiring multiple review cycles before reaching approval
- Delays linked to limited signatory or senior medical capacity
- Bottlenecks appearing during periods that should have been manageable
These issues rarely resolve themselves. They tend to compound as timelines tighten.
“Since partnering with MMD we have found that our materials no longer reach a bottleneck in the copy process. I would recommend them as an agency for companies looking for effective and proactive solution providers.”
Dr Tim Patel
Medical Director UK, Astellas
How My Medical Department Supports Global Programmes
My Medical Department is a physician-led global medical consultancy supporting pharmaceutical and biotech organisations across clinical development, medical affairs and regulatory strategy. Our teams are based in Australia, the UK and Latin America, with project support delivered globally.
We are currently supporting organisations with:
- Managing peak MLR review demand and signatory capacity
- Implementing continuous medical monitoring in clinical programmes
- Strengthening global-to-local regulatory alignment across regions
- Strategic consultancy across clinical development, medical affairs and market access
Where timelines are already under pressure, small structural changes can make a material difference to delivery. If these are challenges your team is currently facing, get in touch to discuss how others are approaching them in practice.
Let us talk about what you are seeing
We support global programmes with teams in Australia, the UK and Latin America. If timelines are already under pressure, the right time to address it is now.
Talk it through with our team →No commitment. Just a conversation.
